Systems Oncology to Present at Upcoming Scientific and Investor Conferences
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Systems Oncology LLC, a privately held biopharmaceutical company developing a new class of multi-modal RNA therapeutics, announced today that the management team will be presenting and participating at the following upcoming conferences:
H.C. Wainwright 23rd Annual Global Investment Conference Company Presentation Presented by Dr. Spyro Mousses, CEO September 10th, 2021, 3:00pm ET Virtual
Wells Fargo 2021 Virtual Healthcare Conference Fireside Chat Presented by Dr. Spyro Mousses, CEO September 10th, 2021, 4:00pm ET Virtual
TIDES USA Conference Arromer - Receptor Directed Delivery for Ultra-precise RNAi Multi-targeting Presented by Dr. Spyro Mousses, CEO September 23rd, 2021, 12:20pm ET Boston, MA
Archived replays of the webcasts following each event will be available on Systems Oncology's website at https://www.systemsoncology.com/news-and-events/
About Systems Oncology:
Systems Oncology is developing a new class of multimodal RNA therapeutics that simultaneously silence the right combination of disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our Arromer platform is used to digitally engineer and rapidly produce self-delivering therapeutics which are directed to specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of drug products in oncology, yet our multimodal RNA therapeutics platform can be harnessed to transform outcomes for any complex polygenic disease.
Company & Investors: Andrew Matricaria, CFO andrew@systemsoncology.com (312) 952-3451
Media: Courtney Villani CVillani@systemsoncology.com (619) 807-1467
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
